Your Location:Home >Products >API >128794-94-5

128794-94-5

  • Product NameMycophenolate mofetil
  • Molecular FormulaC23H31NO7
  • Molecular Weight433.502
  • Purity99%
  • AppearanceWhite powder
Inquiry

Product Details

Quick Details

  • CasNo: 128794-94-5
  • Molecular Formula: C23H31NO7
  • Appearance: White powder
  • Purity: 99%

Reputable Factory Supply Top Purity Mycophenolate mofetil 128794-94-5 with Fast Delivery 

  • Molecular Formula:C23H31NO7
  • Molecular Weight:433.502
  • Appearance/Colour:White powder 
  • Vapor Pressure:7.51E-17mmHg at 25°C 
  • Melting Point:95-96 °C 
  • Refractive Index:1.557 
  • Boiling Point:637.6 °C at 760 mmHg 
  • PKA:5.6(at 25℃) 
  • Flash Point:339.4 °C 
  • PSA:94.53000 
  • Density:1.222 g/cm3 
  • LogP:2.46190 

Mycophenolate mofetil(Cas 128794-94-5) Usage

Description

Mycophenolate mofetil was launched in 1995 in the U.S.A., its first market worldwide, for the prevention of acute kidney transplant rejection in conjunction with other immunosuppressive therapy and to treat refractory acute kidney graft rejection. With improved oral absorption and bioavailability, mycophenolate mofetil is a prodrug of mycophenolic acid (MPA), a fermentation product of several Penicillium species. MPA is a selective, reversible, non-competitive inhibitor of inosinate dehydrogenase and guanylate synthetase. It inhibits the de now pathway of purine biosynthesis. MPA was found to have more potent antiproliferative effects on T and B lymphocytes than other cell types. Compared with other immunosuppressants, mycophenolate mofetil is reportedly superior due to its unique mechanism of action and excellent safety profile for long term use. Mycophenolate mofetil is being investigated clinically in the treatment of heart and liver transplantation rejection, asthma, in preventing coronary artery restenosis, and in treating rheumatoid arthritis.

Chemical Properties

White Powder

Originator

Roche (Switzerland)

Uses

An immunosuppressant.

Definition

ChEBI: A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.

Indications

Mycophenolate mofetil (MMF, CellCept) is an ester prodrug of mycophenolic acid (MPA), a Penicillium-derived immunosuppressive agent that blocks de novo purine synthesis by noncompetitively inhibiting the enzyme inosine monophosphate dehydrogenase. MPA preferentially suppresses the proliferation of cells, such as T and B lymphocytes, that lack the purine salvage pathway and must synthesize de novo the guanosine nucleotides required for DNA and RNA synthesis.MPA has been used for decades as a systemic treatment for moderate to severe psoriasis. MMF was developed to increase the bioavailability of MPA.

Brand name

CellCept

Biochem/physiol Actions

Mycophenolate mofetil is a prodrug of mycophenolic acid (Cat. # M5255) that is cleaved by nonspecific esterases in vivo to produce the parent compound. Mycophenolic acid blocks inosine monophosphate dehydrogenase and is a potent immunosuppresive agent.

Mechanism of action

the guanosine nucleotides required for DNA and RNA synthesis.MPA has been used for decades as a systemic treatment for moderate to severe psoriasis. MMF was developed to increase the bioavailability of MPA.

Clinical Use

MMF is indicated for the prophylaxis of organ rejection in patients receiving renal, hepatic, and cardiac transplants; it is often used in combination with other immunosuppressive agents for this indication. In dermatology, MMF is particularly useful as monotherapy, or as a steroid-sparing agent, for treatment of autoimmune blistering diseases (bullous pemphigoid and pemphigus). It may also be useful for the treatment of inflammatory skin diseases mediated by neutrophilic infiltration, such as pyoderma gangrenosum, and psoriasis.

Side effects

Adverse effects produced by MMF most commonly include nausea, abdominal cramps, diarrhea, and possibly an increased incidence of viral and bacterial infections. Whether MMF may be associated with an increased long-term risk of lymphoma or other malignancies is controversial; however, any such risk is likely to be lower in patients treated for skin disease with MMF monotherapy than in transplant patients treated with combination immunosuppressive therapy.

Drug interactions

Potentially hazardous interactions with other drugs Antipsychotics: avoid with clozapine (increased risk of agranulocytosis). Antivirals: higher concentrations of both mycophenolate and aciclovir or ganciclovir when the two are prescribed concomitantly. Antacids: absorption of mycophenolate decreased in presence of magnesium and aluminium salts. Antibacterials: bioavailability of mycophenolate possibly reduced by metronidazole and norfloxacin; concentration of active metabolite reduced by rifampicin. Colestyramine: 40% reduction in oral bioavailability of mycophenolate. Ciclosporin: some studies show that ciclosporin decreases plasma MPA AUC levels; other studies show increases - no dose change required. Iron preparations: may significantly reduce absorption of mycophenolate. Sevelamer: reduced levels of mycophenolate. Tacrolimus: increases MPA concentrations- no dose change required but monitor closely. See 'Other information'

Metabolism

Mycophenolate undergoes presystemic metabolism in the liver to active mycophenolic acid (MPA). MPA undergoes enterohepatic recirculation and secondary increases in plasma MPA concentrations are seen; these have been reported at between 6-12 hours after a dose of mycophenolate mofetil, and at between 6-8 hours after a dose of mycophenolate sodium. MPA is metabolised by glucuronidation to the inactive mycophenolic acid glucuronide. The majority of a dose of mycophenolate is excreted in the urine as this glucuronide, with negligible amounts of MPA; about 6% of a dose is recovered in faeces.

InChI:InChI=1/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3

128794-94-5 Relevant articles

MYCOPHENOLIC ACID RECYCLING IN A METHOD FOR THE PREPARATION OF MYCOPHENOLATE MOFETIL

-

Page/Page column 8-12, (2009/03/07)

The present invention provides a method ...

METHOD FOR THE PURIFICATION OF MYCOPHENOLATE MOFETIL

-

Page/Page column 7, (2009/03/07)

The present invention provides a method ...

128794-94-5 Process route

2-(morpholin-4-yl)ethanol
622-40-2

2-(morpholin-4-yl)ethanol

mycophenolic acid triethylamine salt

mycophenolic acid triethylamine salt

mycophenolate mofetil
128794-94-5

mycophenolate mofetil

Conditions
Conditions Yield
2-(morpholin-4-yl)ethanol; mycophenolic acid triethylamine salt; In o-xylene; at 110 - 120 ℃; for 44 - 47h; pH=6.8 - 7.3;
With sulfuric acid; In o-xylene; water; at 20 - 28 ℃; pH=2.0 - 7.3;
With sodium hydroxide; In water; ethyl acetate; pH=8.0; Product distribution / selectivity;
 
2-(morpholin-4-yl)ethanol
622-40-2

2-(morpholin-4-yl)ethanol

mycophenolic acid triethylamine salt

mycophenolic acid triethylamine salt

MPA-OH
26644-03-1

MPA-OH

mycophenolate mofetil
128794-94-5

mycophenolate mofetil

C<sub>29</sub>H<sub>42</sub>N<sub>2</sub>O<sub>9</sub>
1094322-91-4

C29H42N2O9

Conditions
Conditions Yield
In xylene; at 120 - 125 ℃; for 3 - 71h; Conversion of starting material;
 

128794-94-5 Upstream products

  • 622-40-2
    622-40-2

    2-(morpholin-4-yl)ethanol

  • 26644-03-1
    26644-03-1

    MPA-OH

;

Relevant Products